Oric Pharmaceuticals
ORIC
70 hedge funds and large institutions have $189M invested in Oric Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 12 closing their positions.
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
39% more call options, than puts
Call options by funds: $163K | Put options by funds: $117K
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
12% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 17
8% more funds holding
Funds holding: 65 → 70 (+5)
3% less capital invested
Capital invested by funds: $194M → $189M (-$5.65M)
9.53% less ownership
Funds ownership: 82.81% → 73.28% (-9.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$1.91M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.04M |
| 4 |
Jane Street
New York
|
+$905K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$828K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.36M |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$1.6M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.4M |
| 4 |
O
OrbiMed
New York
|
-$1.22M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$636K |
ORIC Hedge Fund Activity: Q1 2023 in Review
70 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q1 2023, worth a combined $189M — down 2.9% from $194M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ORIC positions and 12 closed out — a net gain of 5 holders — while 19 added to existing stakes and 17 trimmed.
The largest buyer was Millennium Management, adding an estimated $2M. The largest seller was Artal Group, exiting entirely with an estimated $2.36M sold.
- 70 institutional investors held Oric Pharmaceuticals (ORIC) as of Q1 2023, up from 65 in Q4 2022.
- Funds reported $189M of Oric Pharmaceuticals stock for Q1 2023, down 2.9% quarter-over-quarter.
- 17 funds opened new Oric Pharmaceuticals positions in Q1 2023 and 12 closed out, a net change of +5 holders.
- The largest Oric Pharmaceuticals buyer in Q1 2023 was Millennium Management, an estimated $2M added.
- The largest Oric Pharmaceuticals seller in Q1 2023 was Artal Group, an estimated $2.36M sold.
Based on aggregated 13F filings for Q1 2023.